Methotrexate For The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients (SIGHT)

A Phase I, Multicenter, Uncontrolled, Open Label Study Assessing the Efficacy and Safety of a Combination of Systemic and Intravitreal Injections of Methotrexate for the Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients With RheGmatogenous Retinal DetacHmenT (the SIGHT Study)

Rhegmatogenous retinal detachment (RRD) is a sight-threatening condition. Children with RRD usually present late with clinical features of longstanding RRD, specifically a serious condition named: proliferative vitreoretinopathy (PVR). Therefore, children with RRD often have poorer outcomes. The objective of this study is to investigate the efficacy and safety of methotrexate in the treatment and prevention of PVR. Methotrexate is a medication that has been used to treat inflammatory conditions in children and adults for a long time and it has been recently used to treat PVR in adults.

Study Overview

• Status: Withdrawn
• Conditions: Proliferative Vitreoretinopathy
• Intervention / Treatment: Drug: Methotrexate

• Study Type: Interventional
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Edward H. Wood, MD; Phone Number: (650) 723-6995; Email: ehw@stanford.edu

Study Locations

• United States
  • California
    • Palo Alto, California, United States, 94303
      • Byers Eye Institute at Stanford University and Lucille Packard Children Hospital
      • Contact: Edward Wood, MD; Phone Number: 650-723-6995; Email: ehw@stanford.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 18 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Ability to get informed consent from a parent or a legal guardian of the child and attend all study visits.
2. Males or females 18 years old or younger.
3. Subject is undergoing vitrectomy for either i. initial retinal detachment with or without PVR ii. recurrent retinal detachment due to grade A or higher of proliferative vitreoretinopathy.
4. Female subjects of childbearing potential must not be pregnant or breast-feeding, must have a negative serum pregnancy test at screening, and must be willing to undergo pregnancy tests throughout the study.
5. Female subjects of childbearing potential and male subjects able to father children must (a) abstain from intercourse throughout the course of the study or (b) agree to practice acceptable methods of contraception throughout the course of the study (i.e., intrauterine device, oral contraceptives, barrier method, or other contraception deemed adequate by the investigator).

Exclusion Criteria:

1. Ocular or periocular infection in either eye including (but not limited to):

   1. History of herpetic infection in the study eye(s) or adnexa.
   2. Presence of known active or inactive toxoplasmosis or toxoplasmosis scar in either eye.
   3. History of cytomegalovirus infection or clinical evidence of active cytomegalovirus infection at screening and/or Day 1.
2. Pupillary dilation inadequate for quality stereoscopic fundus photography in the study eye(s).
3. Media opacity that would limit clinical visualization in the study eye(s) and, in the opinion of the investigator, could not be repaired or improved during the RD surgery.
4. Other planned eye surgery during the course of the trial
5. Corneal opacity in the study eye(s) that would preclude reliable assessment of the posterior segment.
6. Uncontrolled glaucoma in the study eye(s), evidenced by an intraocular pressure (IOP) > 21 mmHg while on maximum medical therapy, or chronic hypotony (unmeasurable eye pressure).
7. Subjects should not be currently undergoing treatment with one of the following at the time of RD diagnosis: systemic steroids, methotrexate, azathioprine, or mycophenolate mofetil (or an equivalent drug, e.g., mycophenolic acid) or other immunomodulatory therapies.
8. Malignancy in remission for less than 5 years prior to study participation.
9. Allergy or hypersensitivity to investigational product or other study related procedures/medications.
10. Any recent systemic infection (excluding common cold) within 30 days of Day 1.
11. Known to be immunocompromised.
12. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease condition that contraindicates the use of an investigational drug, might affect the interpretation of the results of the study, or renders the subject at high risk for treatment complications.
13. Any uncontrolled systemic disease, except stable syndromic conditions.
14. Females who are pregnant or lactating and females of child-bearing potential who are not using adequate contraceptive precautions (i.e., intrauterine device, oral contraceptives, barrier method, or other contraception deemed adequate by the investigator).
15. Participation in other investigational drug (oral or topical therapy) or device clinical trials within 30 days prior to Day 1 and/or participation in other investigational drug (intravitreal injection therapy) within 3 months or 5 half-lives (whichever is longer) prior to Day 1 or planning to participate in other investigational drug or device clinical trials during a time which would overlap with the duration of the study. This includes both ocular and non-ocular clinical trials. Exposure to investigational biologics should be discussed with the investigators.
16. In addition, the investigator may declare a subject ineligible for any sound reason.
17. Chest X-ray within 3 months prior to initiation of systemic MTX that shows active pulmonary diseases of any etiology.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment; Methotrexate treatment	Drug: Methotrexate; Systemic and intraoperative intravitreal injection of methotrexate

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Recurrence of Retinal Detachment	Number of Participants with Recurrent Retinal Detachment	6 months

Collaborators and Investigators

• Sponsor: Stanford University
• Investigators: Principal Investigator: Edward Wood, MD, Stanford University; Principal Investigator: Quan Dong Nguyen, MD, MSc, Stanford University; Principal Investigator: Ahmad Al-Moujahed, MD, PhD, MPH, Stanford University; Principal Investigator: Hashem Ghoraba, MD, Stanford University; Principal Investigator: Darius Moshfeghi, MD, Stanford University

Study record dates

Study Major Dates

• Study Start (Anticipated): April 1, 2021
• Primary Completion (Anticipated): April 1, 2023
• Study Completion (Anticipated): April 1, 2024

Study Registration Dates

• First Submitted: March 31, 2021
• First Submitted That Met QC Criteria: March 31, 2021
• First Posted (Actual): April 5, 2021

Study Record Updates

• Last Update Posted (Actual): April 20, 2023
• Last Update Submitted That Met QC Criteria: April 18, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Retinal Diseases; Vitreoretinopathy, Proliferative; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Antirheumatic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Dermatologic Agents; Reproductive Control Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents; Folic Acid Antagonists; Methotrexate
• Other Study ID Numbers: IRB-59989

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No